Peptides in Skin Care: What the Labels Won't Tell You

The skin care aisle has fully embraced peptides. Serums, creams, and eye treatments carry them across every price point — and most of the marketing talks about "collagen-boosting," "firming," and something vague about "regeneration." Some of that is backed by real science. A lot of it isn't. This guide covers the compounds that have genuine evidence, which ones are mechanism-plausible but less proven, why most topical peptide products have a hard biological ceiling, and how to read a label so you actually know what you're buying. This content is produced for research purposes only.

What Peptides Actually Do in Your Skin

Your skin has cells called fibroblasts buried in the dermis — the thick, structural layer sitting beneath the surface you can see. Fibroblasts are your skin's construction crew. They build collagen (the dense fibrous protein that gives skin its firmness), elastin (the springy protein that lets skin bounce back), and the structural proteins that fill the space between them.

Peptides are the signals that tell that crew what to build. Think of them as text messages: short chains of amino acids — typically two to fifty of them linked together — that bind to receptors on fibroblast cells and trigger a production response. The cell receives the message and acts on it. That's the mechanism.

Peptides bind to fibroblast receptors and trigger collagen and elastin production in the dermis.

What the skin care industry figured out is that you can send those signals artificially. Some synthetic peptides mimic the ones your body already produces. Others trigger the same receptors through different molecular pathways. Researchers group them into three functional categories:

• Signal peptides — bind to fibroblast receptors and trigger production of collagen, elastin, and the structural proteins of the extracellular matrix (the fibrous scaffold holding your dermis together)
• Carrier peptides — deliver trace minerals, primarily copper, that enzymes in the dermis need to complete protein synthesis
• Enzyme-inhibitor peptides — slow the enzymes that break collagen down, shifting the net balance toward more collagen without touching the production machinery directly

Most consumer products focus on signal peptides because they address production directly. Carrier and enzyme-inhibitor types tend to appear as supporting ingredients in broader formulations.

The Peptides You'll Find in Skin Care Products

Walk into any pharmacy or department store beauty section and you'll encounter dozens of products listing peptides in their ingredients. A handful of compounds appear across the market most often.

Palmitoyl Peptides (The Matrixyl Family)

The palmitoyl tripeptides — appearing on labels as "palmitoyl tripeptide-1," "palmitoyl pentapeptide-4," or by the trade name Matrixyl — are signal peptides designed to mimic fragments of collagen. As your skin breaks down old collagen during its normal turnover cycle, those fragments signal fibroblasts to ramp up new synthesis. Palmitoyl peptides replicate that signal artificially, short-circuiting the need for actual breakdown.

The palmitoyl group attached to the peptide chain is a fatty acid tail. Its job is to make the peptide more lipid-compatible — which, as you'll see, matters a lot for whether anything actually reaches your fibroblasts.

GHK-Cu (Copper Peptide)

GHK-Cu is the most researched compound in skin biology literature — not just in consumer products, but in the published academic record going back to 1973 (Pickart & Thaler, Nature New Biology, PMID 4349963). It's also the only skin peptide that's a molecule your body makes naturally and produces measurably less of as you age.

For a full breakdown of the GHK-Cu research, including its gene expression effects and how delivery systems determine whether you get those outcomes, see our detailed guide.

Argireline (Acetyl Hexapeptide-3)

Argireline works differently from the peptides above. Rather than triggering collagen synthesis, it interferes with the neuromuscular signalling that causes facial muscles to contract. Think of it as a very mild topical analogue of the mechanism behind botulinum toxin — same general direction, considerably lower effect size, no paralysis.

It appears regularly in eye-area and expression-line products. The mechanism is biologically real. Whether consumer-product concentrations produce clinically meaningful results is a separate question worth holding lightly.

Leuphasyl and Enzyme Inhibitors

Enzyme-inhibiting peptides like Leuphasyl are designed to slow the matrix metalloproteinases — the enzymes your skin uses to break down collagen during normal tissue turnover. Slowing degradation shifts the balance in favour of more collagen without touching the production machinery. These work well as part of a broader stack; in isolation their effects are limited.

Which Ones Have Research Behind Them

Evidence quality varies enormously across this category, and most marketing copy treats a cell-culture finding as equivalent to a clinical result. It isn't. Here's an honest read of where the evidence actually sits:

GHK-Cu sits in a different tier from everything else. The research spans five decades — from Pickart and Thaler's original 1973 isolation through to genomic analyses showing GHK-Cu modulates expression by at least 50% in roughly a third of all human genes across tissue repair, antioxidant defence, and anti-inflammatory pathways (Pickart & Margolina, Int J Mol Sci 2018, PMC6073405). In a placebo-controlled topical study, GHK-Cu application produced collagen increases in 70% of participants — outperforming both vitamin C cream and retinoic acid in the same conditions (Pickart, Vasquez-Soltero & Margolina, Biomed Res Int 2015, PMC4508379).

Research suggests GHK-Cu plasma levels fall roughly 60% between your twenties and your sixties — a decline that tracks closely with reduced skin collagen density and slower wound repair (PMC6073405).

Where the other compounds sit:

• Palmitoyl tripeptides: meaningful in-vitro collagen upregulation data, well-understood mechanism, fewer independent human trials than GHK-Cu
• Argireline: neuromuscular mechanism is real and peer-reviewed; clinical magnitude at consumer product concentrations is less documented
• Leuphasyl and most proprietary blends: mechanism-plausible, typically patent-filed, limited independent clinical evidence

The strongest candidates for actual dermal outcomes — based on published evidence, not marketing — are GHK-Cu and the palmitoyl tripeptide family. Everything else requires more scepticism than the label suggests.

Why Most Peptide Serums Don't Deliver What They Promise

Here's what the marketing never explains: getting a peptide from the surface of your skin to the fibroblasts in the dermis below is genuinely difficult. Your skin evolved specifically to keep foreign molecules out.

The outermost layer — the stratum corneum — functions like a sealed brick wall built from dead skin cells and lipids. It's the reason your skin can survive rain, soap, sweat, and everything else you throw at it. The pharmaceutical rule of thumb for skin penetration is called the 500 Dalton rule: compounds above 500 Daltons in molecular weight generally don't cross intact skin in clinically meaningful quantities (Bos & Meinardi, Exp Dermatol 2000, PMID 10839713).

Most skin care peptides are under 500 Daltons. That sounds encouraging. But molecular weight isn't the only gate.

Polarity matters just as much. GHK-Cu, for instance, weighs around 341 Daltons — small enough in principle. But it's also hydrophilic, meaning it's attracted to water and dissolves easily in it. The stratum corneum is built of lipids. Water-loving molecules partition poorly into fat-based barriers regardless of their size. Most of a hydrophilic peptide applied to the skin surface hits that lipid wall and doesn't cross it.

Users report noticing this limitation in practice: topical peptide products do produce surface-level effects — better hydration, improved texture, barrier support. What they don't consistently reproduce is the dermal-level collagen synthesis changes the clinical research documents. The dermis is a different biological target than the skin surface.

The palmitoyl attachment on palmitoyl peptides partially addresses this problem — the fatty acid tail increases lipid compatibility. It's one reason palmitoyl tripeptides outperform unformulated peptide versions of the same compounds in topical testing. But "more compatible than a plain water-soluble peptide" isn't the same as "crosses the stratum corneum reliably at concentrations that matter."

Reading a Peptide Skin Care Label

When a product claims to contain peptides, the label tells you more than most people notice — if you know what to look for.

Ingredient list position is the most useful starting point. Ingredients are listed in descending order by concentration. A peptide appearing in the top third of the list is present in a meaningful amount. The same peptide appearing near the bottom, after preservatives and fragrance, is almost certainly present at a cosmetic concentration that's more regulatory than functional.

Beyond position, here's what else to check:

• Formulation chemistry. Peptides are fragile. High-acid formulations (like those containing ascorbic acid in oxidising form) can degrade peptides before they reach your skin. The chemistry has to be compatible with the active.
• Packaging. Light and air degrade peptides. Opaque, airtight packaging preserves potency longer than open-jar formats or clear bottles.
• What "peptide complex" actually means. Usually a proprietary blend of several peptides, each at a lower individual concentration than you'd get from a single-peptide product. It reads as comprehensive. It's often more dilute in any single active.
• Absence of a penetration-enhancement mention. An unformulated peptide in a standard serum base is doing less than the same peptide in a formulation designed to help it cross the stratum corneum — even if the label concentration looks identical.

Members experience a wide range of results from topical peptide products, and that variance reflects formula quality as much as the peptide name on the front.

Going Beyond Topical: When You Want Dermal-Level Change

If the goal is surface hydration and texture improvement, a well-formulated topical peptide serum can deliver it. But the published research that generates all the clinical interest — the collagen measurement studies, the genomic analyses, the wound-healing data — was overwhelmingly conducted with systemic delivery or specially engineered penetration systems. Not standard serums.

The dermis, where fibroblasts live, is a different biological target than the skin surface. Reaching it consistently requires either a delivery system engineered to cross the stratum corneum or a route that bypasses the barrier entirely.

Sublingual delivery absorbs peptides directly into the bloodstream, bypassing the skin barrier and digestive system.

Sublingual delivery — placing the compound under the tongue, where mucosal membranes absorb it directly into venous drainage bypassing the digestive system — sidesteps both gut degradation and the stratum corneum. For compounds where the research outcome depends on achieving systemic circulation, the route matters as much as the compound.

VERO's RADIANCE Complex pairs GHK-Cu (5mg) with hyaluronic acid and vitamin C via the VERISORB sublingual delivery system — a formulation designed to extend mucosal contact time and assist permeation for hydrophilic peptides like GHK-Cu. The goal is the systemic compound exposure that the published literature was actually measuring, without requiring an injectable. The delivery mechanism is explained in full here.

Key Takeaways

• Skin peptides are short amino acid chains that act as signals to fibroblasts — the cells that build and maintain your skin's structural scaffold. Signal, carrier, and enzyme-inhibitor peptides each act at a different stage of the same cycle.
• GHK-Cu has the deepest research base in this category: five decades of published evidence, the only skin peptide your body makes measurably less of as you age, and clinical collagen data outperforming both vitamin C cream and retinoic acid in the same conditions (PMID 4349963; PMC6073405).
• Palmitoyl tripeptides (Matrixyl) have meaningful in-vitro collagen data and a well-understood mechanism. Argireline targets neuromuscular contraction, not collagen synthesis. Most other "peptide complexes" are mechanism-plausible but evidence-thin.
• The stratum corneum's lipid barrier limits topical delivery regardless of concentration. The 500 Dalton rule is necessary but not sufficient — a peptide's hydrophilicity determines whether it actually crosses a lipid barrier (PMID 10839713).
• Label position reveals concentration; formulation chemistry reveals stability; packaging reveals whether the active survived to the point of use.
• For dermal-level outcomes, systemic absorption via the sublingual route bypasses both gut and skin barriers — reaching the fibroblasts that the published research was actually targeting.

---

Ready to build a skin protocol that reaches the dermis? Explore the RADIANCE Complex →

---

This content is published for research and educational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, and it does not constitute medical advice. Consult a qualified healthcare professional before making any decisions about your own health. Statements on this page have not been evaluated by the FDA. VERO's peptide products are supplied for research purposes only.

---

References

• Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. 1973;243(122):85–87. https://pubmed.ncbi.nlm.nih.gov/4349963/. Retrieved 2026-05-14.
• Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/. Retrieved 2026-05-14.
• Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015;2015:648108. https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/. Retrieved 2026-05-14.
• Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. Biomed Res Int. 2014;2014:674168. https://pmc.ncbi.nlm.nih.gov/articles/PMC4180391/. Retrieved 2026-05-14.
• Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165–169. https://pubmed.ncbi.nlm.nih.gov/10839713/. Retrieved 2026-05-14.